John Sieckhaus - BioSig Technologies, Chief Officer
| BSGM Stock | USD 1.34 0.04 3.08% |
Insider
John Sieckhaus is Chief Officer of BioSig Technologies, Common
| Age | 56 |
| Phone | 203 409 5444 |
| Web | https://www.biosig.com |
John Sieckhaus Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Sieckhaus against BioSig Technologies, otc stock is an integral part of due diligence when investing in BioSig Technologies,. John Sieckhaus insider activity provides valuable insight into whether BioSig Technologies, is net buyers or sellers over its current business cycle. Note, BioSig Technologies, insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioSig Technologies,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Sieckhaus over six months ago Acquisition by John Sieckhaus of 92300 shares of Biosig Technologies at 0.2603 subject to Rule 16b-3 | ||
John Sieckhaus over a year ago Acquisition by John Sieckhaus of 92300 shares of Biosig Technologies subject to Rule 16b-3 | ||
John Sieckhaus over a year ago Acquisition by John Sieckhaus of 92300 shares of Biosig Technologies subject to Rule 16b-3 | ||
John Sieckhaus over a year ago Acquisition by John Sieckhaus of 295620 shares of Biosig Technologies subject to Rule 16b-3 |
BioSig Technologies, Management Efficiency
The company has return on total asset (ROA) of (4.478) % which means that it has lost $4.478 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (59.7735) %, meaning that it created substantial loss on money invested by shareholders. BioSig Technologies,'s management efficiency ratios could be used to measure how well BioSig Technologies, manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Feinberg | Bluejay Diagnostics | N/A | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Agnes Lee | Inogen Inc | N/A | |
| Michael Favet | Neuropace | 54 | |
| CPA CPA | Cytosorbents Crp | 67 | |
| Skott Greenhalgh | Tela Bio | 56 | |
| Douglas Larson | Beyond Air | 54 | |
| Rebecca Doren | Beyond Air | N/A | |
| Chi Nguyen | Neuropace | 47 | |
| Steven Sloan | Biomerica | 54 | |
| Christopher Smith | Tela Bio | 63 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| William MD | Nuwellis | N/A | |
| Danilo DAlessandro | Clearpoint Neuro | 39 | |
| Roberto JD | Tela Bio | 56 | |
| Jennifer Ernst | Tivic Health Systems | 56 | |
| Danielle Watson | Heart Test Laboratories | 42 | |
| Mazin Sabra | Clearpoint Neuro | 43 | |
| Edward Barger | Beyond Air | N/A | |
| Steven Mertens | Neuroone Medical Technologies | 61 | |
Management Performance
| Return On Equity | -59.77 | ||||
| Return On Asset | -4.48 |
BioSig Technologies, Leadership Team
Elected by the shareholders, the BioSig Technologies,'s board of directors comprises two types of representatives: BioSig Technologies, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioSig. The board's role is to monitor BioSig Technologies,'s management team and ensure that shareholders' interests are well served. BioSig Technologies,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioSig Technologies,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven CPA, Chief Officer | ||
| Frederick Hrkac, Executive President | ||
| John Sieckhaus, Chief Officer | ||
| Budimir Drakulic, Chief Scientist | ||
| Steven Buhaly, Chief Officer | ||
| Gray Fleming, Chief Officer | ||
| Andrew Ballou, Vice Relations | ||
| Kenneth MBA, CEO Founder | ||
| MBA MBA, CEO Founder | ||
| Brenda Castrodad, VP HR | ||
| Michael Fleming, Chief Officer |
BioSig Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is BioSig Technologies, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -59.77 | ||||
| Return On Asset | -4.48 | ||||
| Operating Margin | (227.43) % | ||||
| Current Valuation | 6.43 M | ||||
| Shares Outstanding | 14.12 M | ||||
| Shares Owned By Insiders | 17.59 % | ||||
| Shares Owned By Institutions | 3.04 % | ||||
| Number Of Shares Shorted | 461.7 K | ||||
| Price To Earning | (3.73) X | ||||
| Price To Book | 36.58 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in BioSig OTC Stock
BioSig Technologies, financial ratios help investors to determine whether BioSig OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioSig with respect to the benefits of owning BioSig Technologies, security.